Table 1 Effects of bezafibrate, quinazolinone and its halogenated derivatives on relative liver weights of rats with single and combined hypercholesterolemia compared to normal controls.
From: The antihyperlipidemic activities of 4(3H) quinazolinone and two halogenated derivatives in rats
Single Hypercholesterolemia | Combined Hypercholesterolemia | ||
|---|---|---|---|
Groups | Liver wt./b.wt. | Groups | Liver wt./b.wt. |
N.C | Â | N.C | Â |
Mean ± SD | 0.031 ± 0.005 | Mean ± SD | 0.031 ± 0.005 |
Range | (0.024–0.039) | Range | (0.024–0.039) |
HCD+B | Â | C+B | Â |
Mean ± SD | 0.030 ± 0.003 | Mean ± SD | 0.037 ± 0.005 |
Range | (0.025–0.032) | Range | (0.032–0.045) |
Change% | -11.76 | Change% | 5.71 |
HCD+Q | Â | C+Q | Â |
Mean ± SD | 0.033 ± 0.003 | Mean ± SD | 0.030 ± 0.002 |
Range | (0.029–0.037) | Range | (0.028–0.033) |
Change% | -2.94 | Change% | -14.29 |
HCD+BrQ | Â | C+BrQ | Â |
Mean ± SD | 0.031 ± 0.003 | Mean ± SD | 0.029 ± 0.003 |
Range | (0.028–0.035) | Range | (0.025–0.036) |
Change% | -8.82 | Change% | -17.14 |
HCD+IQ | Â | C+IQ | Â |
Mean ± SD | 0.030 ± 0.002 | Mean ± SD | 0.030 ± 0.001 |
Range | (0.027–0.032) | Range | (0.027–0.031) |
Change% | -11.76 | Change% | -14.29 |